imiquimod has been researched along with Leishmaniasis, American in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Llamas-Molina, JM; Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Choi, HG; Din, FU; Fatima, A; Jamshaid, H; Khan, GM; Khan, S; Khan, SU; Nousheen, K | 1 |
| Gieler, U; Husein-ElAhmed, H; Steinhoff, M | 1 |
| Alsina, M; Fuertes, I; Giavedoni, P; Marti-Marti, I | 1 |
| Becker, I; Bonifaz, A; Fernández-Figueroa, EA; Fuentes-Nava, G; Sánchez-Montes, S; Tirado-Sánchez, A | 1 |
| Blanco, L; Calvo, A; Espuelas, S; Fernández-Rubio, C; Irache, JM; Larrea, E; Moreno, E; Nguewa, P; Sanmartín, C; Schwartz, J | 1 |
| Bastien, P; Bonnet, PA; Bou Youness, H; El Hajj, H; El Hajj, R; Khalifeh, I; Lachaud, L; Masquefa, C | 1 |
| Akhtari, J; Alijani, E; Mehravaran, A; Mirahmadi, H; Nasab, MR; Nikpoor, AR; Sharifi, I | 1 |
| Alkousakis, TJ; Hegg, RM; Swick, BL | 1 |
| Gormley, R; Kovarik, C; Taylor, LA | 1 |
| Calderon, W; Cruz, M; Gyorkos, TW; Llanos-Cuentas, A; Matlashewski, G; Miranda-Verastegui, C; Rahme, E; Tulliano, G; Ward, B | 1 |
| Skinner, RB | 1 |
| Al-Mutairi, N; Alshiltawy, M; Darwish, I; Eassa, BI; El Khalawany, M; Gomaa, S; Joshi, A; Manchanda, Y; Rijhwani, M | 1 |
| Dabiri, S; Javadi, A; Nadji, M; Shamsi Meymandi, M; Shamsi Meymandi, S | 1 |
| Dueñas, J; Hervás, D; Hervás, JA; Martín-Santiago, A; Mena, A; Rocamora, V; Rojo, E | 1 |
| Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA | 1 |
| Daoud, S; Pammer, J; Seeberger, J | 1 |
| Arévalo, I; Llanos-Cuentas, A; Matlashewski, G; Miranda-Verástegui, C; Ward, BJ | 1 |
| Dowlati, Y; Eskandari, SE; Firooz, A; Ghoorchi, MH; Gorouhi, F; Hooshmand, B; Khamesipour, A; Khatami, A; Nassiri-Kashani, M; Rashighi-Firoozabadi, M | 1 |
| Bazarsky, E; El-On, J; Sneir, R | 1 |
| Minodier, P; Parola, P | 1 |
| Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Pollack, H; Quispe, A; Spaeth, G; Tulliano, G | 1 |
| Matlashewski, G; Zhang, WW | 1 |
| Alvarez, E; Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Meng, TC; Miller, R; Najar, E; Ward, B | 1 |
4 review(s) available for imiquimod and Leishmaniasis, American
| Article | Year |
|---|---|
Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta-analysis.
Topics: Combined Modality Therapy; Cryotherapy; Humans; Imiquimod; Leishmaniasis, Cutaneous; Photochemotherapy | 2020 |
Imiquimod as an immune response modulator in infectious conditions.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Child; Condylomata Acuminata; Humans; Imiquimod; Leishmaniasis, Cutaneous; Molluscum Contagiosum | 2002 |
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption | 2012 |
Cutaneous leishmaniasis treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine | 2007 |
5 trial(s) available for imiquimod and Leishmaniasis, American
| Article | Year |
|---|---|
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimony; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunologic Factors; Leishmaniasis, Cutaneous; Male; Middle Aged; Peru; Toll-Like Receptor 7; Treatment Outcome; Young Adult | 2009 |
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Topics: Adjuvants, Immunologic; Administration, Topical; Adolescent; Adult; Aged; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Peru | 2005 |
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Animals; Antimony; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Single-Blind Method; Treatment Outcome | 2006 |
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Animals; Antiprotozoal Agents; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Imiquimod; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pilot Projects; Treatment Outcome | 2007 |
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2001 |
15 other study(ies) available for imiquimod and Leishmaniasis, American
| Article | Year |
|---|---|
Old World Cutaneous Leishmaniasis: Successful response to topical imiquimod.
Topics: Adjuvants, Immunologic; Humans; Imiquimod; Leishmaniasis, Cutaneous | 2022 |
Mannosylated imiquimod-terbinafine co-loaded transethosomes for cutaneous leishmaniasis; assessment of its anti-leishmanial potential, in vivo safety and immune response modulation.
Topics: Animals; Imiquimod; Immunity; Leishmania major; Leishmaniasis, Cutaneous; Mice; Terbinafine | 2023 |
Cutaneous leishmaniasis of the face treated with imiquimod 3.75.
Topics: Humans; Imiquimod; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2021 |
Efficacy of imiquimod 5% cream as first-line management in cutaneous leishmaniasis caused by Leishmania mexicana.
Topics: Adult; Humans; Imiquimod; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Mexico; Young Adult | 2021 |
Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Topics: Animals; Antibodies; Antiprotozoal Agents; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Imiquimod; Inflammation Mediators; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Mice, Inbred BALB C; Neutrophil Infiltration; Paromomycin; Skin; Tumor Necrosis Factor-alpha | 2018 |
EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.
Topics: Humans; Imiquimod; Leishmania major; Leishmania tropica; Leishmaniasis, Cutaneous; NF-kappa B; Quinoxalines; Syria; Toll-Like Receptors | 2018 |
Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis.
Topics: Adjuvants, Immunologic; Animals; Antigens, Protozoan; Female; Imiquimod; Leishmania major; Leishmaniasis, Cutaneous; Liposomes; Mice; Mice, Inbred BALB C | 2019 |
What is your diagnosis? Old world Leishmaniasis.
Topics: Aminoquinolines; Anti-Infective Agents; Arm; Cryotherapy; Fluconazole; Humans; Imiquimod; Iraq; Leishmania major; Leishmaniasis, Cutaneous; Male; Military Personnel; Young Adult | 2014 |
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis.
Topics: Aminoquinolines; Antiprotozoal Agents; Cytoreduction Surgical Procedures; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous | 2017 |
Tropical medicine rounds: Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Ambulatory Care Facilities; Aminoquinolines; Anti-Infective Agents; Antiprotozoal Agents; Combined Modality Therapy; Cryotherapy; Dapsone; Drug Therapy, Combination; Female; Humans; Imiquimod; Itraconazole; Kuwait; Leishmaniasis, Cutaneous; Male; Middle Aged; Treatment Outcome; Young Adult | 2009 |
Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminoquinolines; Animals; Antigens, CD; Antigens, CD1; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antiprotozoal Agents; B-Lymphocytes; CD3 Complex; Child; Dermis; Drug Therapy, Combination; Epidermis; Female; Humans; Imiquimod; Iran; Langerhans Cells; Leishmania tropica; Leishmaniasis, Cutaneous; Lymphocyte Count; Macrophages; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Parasite Load; Single-Blind Method; T-Lymphocytes; Young Adult | 2011 |
Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.
Topics: Administration, Topical; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Child; Humans; Imiquimod; Leishmania infantum; Leishmaniasis, Cutaneous; Liposomes; Male; Treatment Failure; Treatment Outcome | 2012 |
Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.
Topics: Adjuvants, Immunologic; Administration, Topical; Adolescent; Adult; Aminoquinolines; Female; Humans; Imiquimod; Leishmaniasis, Cutaneous; Male; Prospective Studies; Time Factors; Treatment Outcome | 2003 |
Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Benzethonium; Drug Therapy, Combination; Imiquimod; Leishmania major; Leishmaniasis, Cutaneous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Ointments; Paromomycin; Rabbits | 2007 |
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antigens, Protozoan; Female; Foot; Imidazoles; Imiquimod; Injections, Intramuscular; Injections, Subcutaneous; Interferon-gamma; Leishmania major; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Lymphocytes; Mice; Mice, Inbred BALB C; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2008 |